Ligand Pharmaceuticals (NASDAQ:LGND) stock surged 6.32% in intraday trading on Thursday after reporting better-than-expected fourth quarter 2024 earnings and providing an optimistic outlook for 2025.
For the fourth quarter, Ligand posted adjusted earnings per share of $1.27, beating the consensus analyst estimate of $1.19. Total revenue of $42.81 million also exceeded expectations of $39.02 million. The strong quarterly results were driven by a 52.35% year-over-year increase in sales.
Looking ahead, Ligand forecasts full-year 2025 adjusted EPS of $6.00 to $6.25 on projected revenue between $180 million and $200 million. Analysts were expecting EPS of $6.07 on revenue of $187.1 million, so the company's guidance came in largely ahead of estimates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.